{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:26:31Z","timestamp":1785893191538,"version":"3.56.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplant recipients (allo-HCTRs) with positive cytomegalovirus (CMV) serology may have false-positive results due to blood product transfusion\u2013associated passive immunity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-center cohort study included allo-HCTRs with negative baseline (at malignancy diagnosis) CMV serology and indeterminate\/low-positive (CMV IgG titer, \u22650.6\u2013&amp;lt;50 U\/mL) pretransplant CMV serology with negative pretransplant plasma CMV DNAemia. The CMV status of those patients was reclassified from R+ to R\u2212 (CMVR\u2212 reclassification group). We compared those patients to allo-HCTRs with negative (CMV IgG titer &amp;lt;0.6 U\/mL) pretransplant CMV IgG (CMVR\u2212 group). We describe the number and type of patients whose pretransplant CMV status was reclassified from indeterminate\/positive to negative. We reviewed all plasma CMV DNAemia tests performed during the first 6 months posttransplant in both groups to assess the safety of this approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 246 (84.5%) of 291 transplanted patients identified as CMVR+ pretransplant, 60 (24.4%) were reclassified from CMV serology indeterminate (N:10)\/low-positive (N:50) to R\u2212. Only 1 of 60 patients (1.67%) in the CMVR\u2212 reclassification group versus 3 of 44 (6.8%; P = .30) in the CMVR\u2212 group developed CMV DNAemia during the follow-up period. There were no significant differences in the number of CMV DNAemia tests performed, CMV DNAemia range, and time posttransplant between the 2 groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>One of 4 allo-HCT CMVR+ may be falsely flagged as R+, with significant impact on donor selection and prophylaxis administration. A 2-step approach including CMV serology testing at hematologic malignancy diagnosis in allo-HCT candidates and careful review of pretransplant CMV IgG titers may help correctly classify CMV serology status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad550","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T17:11:27Z","timestamp":1694797887000},"page":"423-429","source":"Crossref","is-referenced-by-count":16,"title":["Revisiting Cytomegalovirus Serology in Allogeneic Hematopoietic Cell Transplant Recipients"],"prefix":"10.1093","volume":"78","author":[{"given":"Vera","family":"Portillo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Royston","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Laboratory Medicine Division, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schibler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland"},{"name":"Laboratory of Virology, Laboratory Medicine Division, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mappoura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Morin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Giannotti","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Mamez","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"van Delden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[{"name":"Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-2869","authenticated-orcid":false,"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"2024021719314366000_ciad550-B1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2024021719314366000_ciad550-B2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"2024021719314366000_ciad550-B3","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV Serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"2024021719314366000_ciad550-B4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V124.21.1207.1207","article-title":"Patient\/donor CMV matching is a critical determinant of survival in unrelated donor haematopoietic stem cell transplantation","volume":"124","author":"Shaw","year":"2014","journal-title":"Blood"},{"key":"2024021719314366000_ciad550-B5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/tme.12264","article-title":"Transfusion of CMV-unselected blood components may lead to inappropriate donor selection for patients subsequently undergoing allogeneic stem cell transplant","volume":"25","author":"Morton","year":"2015","journal-title":"Transfus Med"},{"key":"2024021719314366000_ciad550-B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bjh.17754","article-title":"Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients: A British Society for Haematology Good Practice Paper","volume":"195","author":"Morton","year":"2021","journal-title":"Br J Haematol"},{"key":"2024021719314366000_ciad550-B7","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1537-2995.2011.03203.x","article-title":"Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)","volume":"51","author":"Thiele","year":"2011","journal-title":"Transfusion"},{"key":"2024021719314366000_ciad550-B8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/vaccines9040372","article-title":"Letermovir primary prophylaxis in high-risk hematopoietic cell transplant recipients: a matched cohort study","volume":"9","author":"Royston","year":"2021","journal-title":"Vaccines"},{"key":"2024021719314366000_ciad550-B9","doi-asserted-by":"crossref","first-page":"ofad169","DOI":"10.1093\/ofid\/ofad169","article-title":"CMV Infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients","volume":"10","author":"Chavaz","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024021719314366000_ciad550-B10","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024021719314366000_ciad550-B11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024021719314366000_ciad550-B12","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Kolk LE","year":"2002","journal-title":"Blood"},{"key":"2024021719314366000_ciad550-B13","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.bbmt.2020.07.034","article-title":"Impact of anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors on CMV reactivation","volume":"26","author":"Arcuri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024021719314366000_ciad550-B14","doi-asserted-by":"crossref","first-page":"683.e1","DOI":"10.1016\/j.jtct.2021.04.024","article-title":"Prediction of cytomegalovirus reactivation by recipient cytomegalovirus-IgG titer before allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Kawamura","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad550\/54083115\/ciad550.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/423\/56697754\/ciad550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/423\/56697754\/ciad550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T19:32:34Z","timestamp":1708198354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/2\/423\/7274728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2024,2,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad550","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,15]]},"published":{"date-parts":[[2023,9,15]]}}}